Anaphylm's NDA resubmission after a human-factors CRL tests whether a sublingual epinephrine film can win FDA approval and displace the auto-injector standard of care

Bull

A successful resubmission that fully addresses the human factors validation deficiencies — demonstrating that revised packaging enables reliable pouch opening and correct sublingual film placement across all user groups — combined with supportive PK data, results in FDA approval and triggers the $20M Oaktree tranche. This would validate sublingual epinephrine film as a viable auto-injector alternative, opening a large anaphylaxis rescue market and enabling the expanded 75-person field force to drive commercial uptake.

Bear

The most likely failure mode is a second CRL stemming from residual human factors deficiencies — specifically if the revised container closure design still shows unacceptable error rates in pouch opening or film placement during the validation study, particularly in pediatric or elderly user groups. A second rejection would severely damage credibility with investors and could jeopardize the RTW partnership deadline of June 30, 2027, while leaving the company dependent on the sunsetting Suboxone royalty stream.